SIGA to Present at the 14th Annual Wells Fargo Securities Healthcare Conference on September 5, 2019

NEXT STORY
Media Statement Veyonda® Enhances Radiotherapy in Prostate Cancer Treatment Further Promising Results
PREV STORY
ContraFect Announces Presentation of New Data from its Amurin Peptide Program at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

COVID-19 Testing Market Update 2021: A 38 Billion Dollar Market for COVID-19 Test Products: Molecular, Antigen, and Antibody Tests

author_avatar
NASDAQ Market News

Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021

author_avatar
NASDAQ Market News

Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613® (devimistat) for Patients with Relapsed or Refractory Burkitt’s Lymphoma/Leukemia to Massachusetts General Hospital in Boston

author_avatar
NASDAQ Market News